Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease

Experimental Neurology

Volumn 188, Issue 2, 2004, Pages 491-494

  Shults, Clifford W ^a,b   Beal, M Flint ^c   Song, David ^a,b   Fontaine, Deborah ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Coenzyme Q10; Mitochondria; Parkinson disease; Ubiquinone

Indexed keywords

ALBUMIN; ALPHA TOCOPHEROL; CREATINE KINASE; ROPINIROLE; UBIDECARENONE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HUMAN; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOMAGNESEMIA; HYPOPARATHYROIDISM; MALE; MEASUREMENT; PARKINSON DISEASE; PATIENT; PILOT STUDY; PRIORITY JOURNAL; THORAX PAIN;

CALCIUM; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; DYSPEPSIA; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; PILOT PROJECTS; SAFETY; TIME FACTORS; UBIQUINONE; VITAMIN E;

EID: 3042717908     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2004.05.003     Document Type: Article

References (15)

1. Alleva R., Tomasetti M., Bompadre S., Littarru G.P. Oxidation of LDL and their subfractions: kinetic aspects and CoQ10 content. Mol. Aspects Med. 18:1997;S105-S112. (Suppl.)
2. Bogentoft C., Edelund P.O., Olsson B., Widlund L., Westensen K. Biopharmaceutical aspects of intravenous and oral administration of coenzyme Q10. Folkers K., Littarru G.P., Yamagami T. Biomedical and Clinical Aspects of Coenzyme Q. 1991;215-224 Elsevier, Amsterdam/New York
3. Constantinescu A., Maguire J.J, Packer L. Interactions between ubiquinones and vitamins in membranes and cells. Mol. Aspects Med. 15:1994;57-65. (Suppl.)
4. Kontush A., Hubner C., Finckh B., Kohlschutter A., Beisiegel U. Antioxidative activity of ubiquinol-10 at physiological concentrations in human low density lipoprotein. Biochim. Biophys. Acta. 1258:1995;177-187
5. Lang A.E. Clinical rating scales and videotape analysis. Koller W.C., Paulson G. Therapy of Movement Disorders. second ed. 1995;21-46 Marcel Dekker, New York
6. Lass A., Sohal R.S. Electron transport-linked ubiquinone-dependent recycling of α-tocopherol inhibits autooxidation of mitochondrial membranes. Arch. Biochem. Biophys. 352:1998;229-236
7. 10 and α-tocopherol content of mitochondria on the production of superoxide anion radicals. FASEB J. 14:2000;87-94
8. Lucker P.W., Wetselsberger N., Hennings G., Rehn D. Pharmacokinetics of coenzyme ubidecarenone in healthy volunteers. Folkers K., Littarru G.P., Yamagami T. Biomedical and Clinical Aspects of Coenzyme Q. 1984;143-151 Elsevier
9. Mohr D., Bowry V.W., Stocker R. Dietary supplementation with coenzyme Q10 results in increased levels of ubiquinol-10 within circulating lipoproteins and increased resistance of human low-density lipoprotein to the initiation of lipid peroxidation. Biochim. Biophys. Acta. 1126:1992;247-254
10. Okamoto T., Matusuya T., Fukunaga Y., Kishi T., Yamagami T. Human serum ubiquinol-10 levels and relationship to serum lipids. Int. J. Vitam. Nutr. Res. 59:1989;288-292
11. Shults C.W. Treatments of Parkinson's disease: circa 2003. Arch. Neurol. 60:2003;1680-1684
12. 10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59:2002;1541-1550
13. Stocker R., Bowry V.W., Frei B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol. Proc. Natl. Acad. Sci. U. S. A. 88(5):1991;1646-1650
14. Tomono Y., Hasegawa J., Seki T., Motegi K., Morishita N. Pharmacokinetic study of deuterium-labelled coenzyme Q10 in man. Int. J. Clin. Pharmacol., Ther. Toxicol. 24:1986;536-541
15. Weis M., Mortensen S.A., Rassing M.R., Moller-Sonnergaard J., Poulsen G., Rassmussen S.N. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers. Mol. Aspects Med. 15:1994;273-280